The estimated Net Worth of Joanne Quan is at least $168 Tausend dollars as of 2 April 2018. Joanne Quan owns over 4,000 units of Mirum Pharmaceuticals Inc stock worth over $167,640 and over the last 9 years Joanne sold MIRM stock worth over $0.
Joanne has made over 1 trades of the Mirum Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Joanne exercised 4,000 units of MIRM stock worth $8,240 on 2 April 2018.
The largest trade Joanne's ever made was exercising 4,000 units of Mirum Pharmaceuticals Inc stock on 2 April 2018 worth over $8,240. On average, Joanne trades about 667 units every 0 days since 2016. As of 2 April 2018 Joanne still owns at least 4,000 units of Mirum Pharmaceuticals Inc stock.
You can see the complete history of Joanne Quan stock trades at the bottom of the page.
Joanne's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY, CA, 94404.
Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: